Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBINE: Peginterferon alfa-2a Addition in Chronic Hepatitis B
NCT02894918Phase 4Unknown
- Sponsor
- Henan Provincial People's Hospital
- Start
- Sep 2016
- Primary completion
- Jun 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2a in Chronic Hepatitis B (CHB) (2 arms), sponsored by Henan Provincial People's Hospital. Primary endpoint: The rate of HBsAg loss at 48 weeks. Status: unknown.
02
Drugs
peginterferon alfa-2a
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02894918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02894918.